UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2023

Commission File Number: 001-37710


HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)


48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F               Form 40-F  


HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

Exhibit No.

    

Description

Exhibit 99.1

Announcement relating to blocklisting six monthly return

Exhibit 99.2

Announcement relating to total voting rights

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HUTCHMED (CHINA) LIMITED

By:

/s/ Johnny Cheng

Name:

Johnny Cheng

Title:

Chief Financial Officer

Date: December 29, 2023

3


Exhibit 99.1

Graphic

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

1.

Name of applicant:

HUTCHMED (China) Limited

2.

Name of scheme:

(a)

Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option Scheme”)

(b)

Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”)

3.

Period of return:

From June 29, 2023 to December 28, 2023

4.

Balance under scheme from previous return:

(a)

2005 HUTCHMED Share Option Scheme: 434,050 ordinary shares of US$0.1 each

(b)

2015 HUTCHMED Share Option Scheme: 51,730,718 ordinary shares of US$0.1 each

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

(a)

2005 HUTCHMED Share Option Scheme: Nil

(b)

2015 HUTCHMED Share Option Scheme: Nil

6.

Number of securities issued/allotted under scheme during period:

(a)

2005 HUTCHMED Share Option Scheme: 211,320

(b)

2015 HUTCHMED Share Option Scheme: 4,883,500

7.

Balance under scheme not yet issued/allotted at end of the period:

(a)

2005 HUTCHMED Share Option Scheme: 222,730 ordinary shares of US$0.1 each (Note: All granted share options have been exercised)

(b)

2015 HUTCHMED Share Option Scheme: 46,847,218 ordinary shares of US$0.1 each

8.

Number and class of securities originally listed and the date of admission:

25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission schemes following the Company’s share subdivision which took effect on May 30, 2019)

9.

Total number of securities in issue at the end of the period:

871,256,270 ordinary shares of US$0.1 each

Name of contact:

Weiguo Su

Address of contact:

Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong

Telephone number of contact:

+852 2121 8200


About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries

+852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com

Media Enquiries

Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com

Zhou Yi, Brunswick

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley / Daphne Zhang,

Panmure Gordon

+44 (20) 7886 2500


Exhibit 99.2

Graphic

Total Voting Rights



Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at December 29, 2023, the issued share capital of HUTCHMED consisted of 871,256,270 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 871,256,270 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 871,256,270 ordinary shares would be equivalent to 871,256,270 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,251,254 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S.. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Contacts

Investor Enquiries

+852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com

Media Enquiries

Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) /

+44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com

Zhou Yi, Brunswick

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon

+44 (20) 7886 2500



HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more HUTCHMED China Charts.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more HUTCHMED China Charts.